IFNβ

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and development of innovative interferon therapies are key factors fueling the expansion of the interferon market from 2025 to 2032. LAS VEGAS, March 5, 2025 /PRNewswire/ -- DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading interferons companies' market shares, challenges, interferons market drivers, barriers, trends, and key market interferons companies in the market. Key Takeaways from the Interferons Market Report As per DelveInsight estimates, North America is anticipated to dominate the global interferons market during the forecast period. In the application segment of the interferon market, the leukemia category captured a significant revenue share in 2024. Notable interferons companies such as Bayer AG, Amega Biotech, Biogen, Merck KGaA, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Biosidus, AOP Orphan Pharmaceuticals GmbH, Reliance Life Sciences, and several others, are currently operating in the interferons market. In September 2022, Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration (FDA). To read more about the latest highlights related to the interferons market, get a snapshot of the key highlights entailed in the Global Interferons Market Report Interferons Overview Interferons (IFNs) are a group of signaling proteins that play a critical role in the immune response, particularly in defending against viral infections and modulating the activity of immune cells. They are classified into three main types: Type I (such as IFN-α and IFN-β), Type II (IFN-γ), and Type III (IFN-λ). Type I interferons are primarily produced in response to viral infections and function by activating antiviral pathways in host cells, inhibiting viral replication, and enhancing the activity of natural killer (NK) cells. IFN-γ, the sole Type II interferon, is crucial for activating macrophages and promoting adaptive immune responses, particularly in bacterial and tumor immunity. Type III interferons share functional similarities with Type I IFNs but act more selectively on epithelial cells, making them important in mucosal immunity. Beyond their antiviral properties, interferons have significant roles in cancer immunotherapy and autoimmune diseases. They enhance antigen presentation, stimulate cytotoxic T cells, and modulate the tumor microenvironment, contributing to immune surveillance against malignancies. Clinically, recombinant interferons have been used to treat conditions such as hepatitis B and C, multiple sclerosis, and certain cancers. However, prolonged interferon therapy can lead to adverse effects, including flu-like symptoms, fatigue, and autoimmune complications. Recent research is focused on optimizing interferon-based therapies and combining them with immune checkpoint inhibitors or other immunomodulators to improve efficacy while minimizing toxicity. Interferons Market Insights North America holds the largest interferons market share due to a strong presence of biopharmaceutical companies, robust R&D investments, and high healthcare expenditure. The U.S. market, in particular, benefits from a well-established regulatory framework and widespread adoption of advanced biotherapeutics. Meanwhile, Europe follows closely, with key contributions from Germany, France, and the UK, where government support for biotech innovation and access to novel biologics drive market expansion. In the Asia-Pacific region, the interferon market is witnessing rapid growth, fueled by rising healthcare infrastructure, an increasing prevalence of infectious diseases, and government initiatives to boost biopharmaceutical production. China and India are emerging as major players, with domestic companies investing heavily in biosimilar development and expanding manufacturing capacities. Latin America and the Middle East & Africa are also showing potential, albeit at a slower pace, due to improving healthcare access and growing awareness of biologic treatments. However, market expansion in these regions is challenged by high drug costs and regulatory hurdles, which may impact the adoption of interferon therapies. To know more about why North America is leading the market growth in the interferons market, get a snapshot of the Interferons Market Outlook Interferons Market Dynamics The interferons market is driven by their critical role in treating viral infections, autoimmune diseases, and various cancers. Interferons (IFNs) are a class of cytokines that modulate the immune response, making them valuable in antiviral therapies (such as hepatitis B and C), multiple sclerosis, and oncology applications. The increasing prevalence of these diseases, along with rising research into novel interferon-based therapies, continues to fuel market growth. However, the market faces challenges due to the emergence of alternative therapies, such as monoclonal antibodies and small-molecule inhibitors, which offer higher efficacy and fewer side effects. One of the key factors influencing market dynamics is the shift from traditional interferon therapies to newer, more targeted treatments. For instance, in the treatment of hepatitis C, direct-acting antiviral agents (DAAs) have largely replaced interferon-based regimens due to their superior cure rates and reduced adverse effects. Similarly, in multiple sclerosis, oral therapies and monoclonal antibodies such as ocrelizumab and natalizumab have overshadowed interferon-beta treatments. Despite this, interferons remain relevant in certain applications, such as rare cancers and specific immune disorders where alternative treatments are not as effective. Another factor shaping the interferons market is the regulatory landscape. Interferons are biologic drugs, meaning they are subject to stringent approval processes and high production costs. The development of biosimilar interferons has the potential to make these therapies more accessible, especially in emerging markets. However, biosimilars face challenges in gaining market traction due to concerns about immunogenicity and physician preference for established brands. Companies investing in next-generation interferons with improved efficacy and safety profiles may have an opportunity to capture a share of this evolving market. Looking ahead, the future of the interferons market will be shaped by ongoing innovation, competitive pressures, and the need for cost-effective biologics. While traditional interferon therapies may continue to decline in some areas, their role in niche indications and combination therapies could sustain market demand. Companies focusing on improving delivery methods, reducing side effects, and exploring novel interferon applications in immuno-oncology and rare diseases may unlock new growth opportunities in this evolving landscape. Get a sneak peek at the interferons market dynamics @ Interferons Market Dynamics Analysis Interferons Market Assessment Interferons Market Segmentation Interferons Market Segmentation By Type: Alpha, Beta, and Gamma Interferons Market Segmentation By Application: Hepatitis B, Hepatitis C, Leukemia, Multiple Sclerosis, and Others Interferons Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Interferons Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the interferons market are set to emerge as the trendsetter explore @ Interferons Companies Table of Contents Interested in knowing the interferons market by 2032? Click to get a snapshot of the Interferons Market Trends Related Reports Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, among others. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, among others. Chronic Hepatitis B Market Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic hepatitis B companies, including GlaxoSmithKline, Ionis Pharma, Beijing Continent Pharmaceutical, Ascletis Pharmaceuticals, Vir Biotechnology, Brii Biosciences, Janssen, Arrowhead Pharmaceuticals, among others. Chronic Hepatitis B Pipeline Chronic Hepatitis B Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic hepatitis B companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Nov. 18, 2024 -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA granted both Orphan Drug and Rare Pediatric Disease designations to SRN-101, supporting its development as a new therapy for patients with high-grade gliomas and pediatric-type diffuse high-grade gliomas, respectively, some of the most aggressive brain cancers with few therapeutic options. This marks a significant milestone for the company as it advances efforts to address the urgent unmet needs of adult and pediatric patients with high-grade gliomas. “SRN-101 has the potential to address a critical gap in effective high-grade glioma therapies by leveraging the body’s immune response in a targeted, innovative way," said Dr. Nicholas Butowski, MD, Neuro-Oncologist and Director of Translational Research in Neuro-Oncology at the University of California, San Francisco. "This approach could represent a major breakthrough in how we treat one of the most devastating brain cancers and offers a new path of hope for patients." SRN-101 is a recombinant adeno-associated viral (AAV) vector expressing an engineered cytokine. Last year, Siren Biotechnology, a VC-backed company, launched with preclinical data demonstrating that their universal AAV immuno-gene therapies exhibited potent anti-tumor effects in preclinical models of brain cancer [read more], and was additionally awarded a $4M CIRM TRAN1 grant to support the development of these therapies [read more]. SRN-101 for high-grade gliomas is the first asset and indication to be revealed from Siren Biotechnology’s universal AAV immuno-gene therapy platform, with additional technology innovations and other solid tumor indications in development. “We are excited to announce SRN-101 as the lead universal AAV immuno-gene therapy asset in our platform’s pipeline,” said Dr. Nicole K. Paulk, PhD, Siren Biotechnology’s CEO and Founder. “Our team has worked tirelessly to develop an approach that demonstrates remarkable promise for the treatment of high-grade gliomas but also has transformative potential for use in additional indications.” Headquartered in San Francisco, CA, Siren Biotechnology is sounding the alarm against cancer. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer. The content above comes from the network. if any infringement, please contact us to modify.

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Exo Therapeutics, Inc. , a pre-clinical company developing a pipeline of drug candidates that target exosites, unique small-molecule binding pockets that are distinct from traditional active and allosteric sites, to reprogram target enzyme activity for precise and robust therapeutic effects, today presented a late-breaking poster on its preclinical program targeting the TBK1/STING interaction of the cGAS-STING pathway at the American College of Rheumatology’s Convergence Conference (ACR) in Washington, D.C. Aberrant activation of the cGAS/TBK1-/STING pathway has been shown to be linked to autoimmune diseases like SLE, CLE, SSc and Sjögren’s. Historically, inhibiting this pathway has proven to be difficult for active-site inhibitors due to their inadequate selectivity, which can lead to off-target effects and narrow therapeutic indices. Exo’s approach seeks to overcome these challenges with its novel exosite inhibitors that disrupt STING-mediated TBK1 activation while avoiding the beneficial functions of the kinase on viral suppression and maintenance of autophagy. Data presented show that EXO-TBKis, novel TBK1 inhibitors that selectively and potently inhibit the TBK1/STING pathway, demonstrated efficacy in multiple cellular and mouse models as well as patient-derived samples. These findings support the company’s nomination of a lead development candidate for the treatment of autoimmune diseases such as Systemic and Cutaneous Lupus (SLE and CLE), Systemic Sclerosis (scleroderma, SSc) and Sjögren’s Syndrome. “Exo’s TBK1 selective exosite inhibitors have demonstrated their ability to potently and selectively inhibit pathogenic effects of TBK1/STING, while sparing beneficial antiviral and cellular functions,” said Dr. Jörg Distler, University of Erlangen. “This approach has the potential to deliver therapeutic benefit to individuals living with autoimmune diseases like SSc and I’m looking forward to the nomination of their lead development candidate based on these promising data.” Data show that an EXO-TBK1i displayed exceptional exosite binding affinity on the target (IC50 -9nM), that translates into double-digit nanomolar potencies in human monocytes, THP1 cells, monocytes and mouse macrophages. EXO-TBK1i were also shown to demonstrate enhanced selectivity when compared to a TBK1 active-site, cGAS and STING inhibitors. Additionally, EXO-TBK1is were shown to preserve autophagy, while sparing RIG-I activity with 100-fold selectivity, two activities that are linked to effective immune responses to infection. Dose dependent suppression of p-TBK1, p-STING and inflammatory cytokines were observed in a STING activated DMXAA mouse model. In a disease model, TREX-1 null mouse, EXO-TBK1i was shown to suppress heart inflammation with a dramatic reduction of proinflammatory cytokines including IFNβ, CXCL-10, CXCL-9 and IFIT1. The TBK1i also displayed dose-dependent inhibition of p-TBK1, p-STING, p-IRF3 and p-P65 in the TREX-1 model. Most notably, EXO-TBK1i demonstrated robust effects in SLE and SSc patient samples. When assessed for activity in SLE patient-derived human whole blood and PBMC, EXO-TBK1i robustly suppressed pathway activation. Similarly, EXO-TBK1i significantly suppressed pathway activation and expression of SMA and stress fibers in SSc patient-derived fibroblasts. Details of the poster presentations are as follows: Abstract Title: Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases Presenting Author: Bhavatarini Vangamudi, Ph.D. Presentation Type: Poster Session: Late-Breaking Posters (L01 - L14) Date: Monday, November 18 Presentation Time: 10:30 AM - 12:30 PM Abstract ID: 1943848 Final Number: L01 About Exo Therapeutics Exo Therapeutics is a small molecule drug discovery and development company co-founded by Professors David R. Liu, Alan Saghatelian and Juan Pablo Maianti with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight TM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company's team of world-class researchers is unlocking breakthrough therapeutics in inflammation, oncology and a broad range of other diseases. For more information, visit www.exo-therapeutics.com .